SequelSEC

Olema Pharmaceuticals, Inc. OLMA

Pharmaceutical Preparations · CIK 0001750284 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$178.70M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Olema Pharmaceuticals, Inc. (OLMA) reported net income of -$162.45M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Olema Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Olema Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$178.70M-$142.26M-$104.96M-$106.99M-$71.49M-$21.53M-$4.32M
Net income-$162.45M-$129.47M-$96.66M-$104.79M-$71.10M-$22.12M-$4.32M
Research & development$157.70M$124.52M$86.14M$82.27M$51.10M$13.70M$3.92M
Weighted-average diluted sharesshares 87.01Mshares 58.74Mshares 45.25Mshares 40.00Mshares 39.52Mshares 7.02Mshares 2.59M
Pretax income-$162.45M-$129.47MUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$3.00K$2.00K$2.00K$1.00KUnavailableUnavailableUnavailable
Diluted EPS$-1.87$-2.20$-2.14$-2.62$-1.80$-3.42$-1.66
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$21.00M$17.74M$18.82M$24.71M$20.39M$7.82M$403.00K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Olema Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$48.30M$139.48M$68.54M$23.70M$13.81M$338.55MUnavailable
Total assets$533.43M$450.98M$276.94M$215.64M$295.94M$342.72MUnavailable
Current assets$515.45M$438.47M$266.51M$208.90M$290.68M$342.14MUnavailable
Total liabilities$54.87M$42.02M$23.05M$18.10M$11.38M$4.58MUnavailable
Current liabilities$51.80M$41.76M$21.62M$16.55M$9.02M$4.58MUnavailable
Total equity incl. NCI$478.56M$408.96M$253.90M$197.55M$284.57M$338.14M-$10.59M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$9.25M$4.46M$2.70M$374.00K$23.00K$719.00KUnavailable

Cash flow

Olema Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$146.72M-$104.35M-$83.73M-$82.06M-$50.69M-$19.87M-$3.08M
Capital expendituresUnavailable$159.00KUnavailable$363.00K$1.58M$56.00KUnavailable
Investing cash flow-$155.76M-$93.53M-$4.85M$91.48M-$275.44M-$56.00KUnavailable
Financing cash flow$211.30M$268.82M$133.42M$476.00K$1.39M$358.40MUnavailable
Net change in cash-$91.18M$70.94M$44.84M$9.89M-$324.74M$338.48M-$3.08M
Stock-based compensation$17.59M$22.58M$17.26M$18.83M$15.91M$3.11MUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$490.00K$393.00K$377.00K$357.00K$163.00K$11.00K$9.00K

Derived

Olema Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailable-$104.51MUnavailable-$82.43M-$52.26M-$19.92MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio9.95x10.50x12.33x12.62x32.23x74.62xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OLMA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.